Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
139 hedge funds and large institutions have $775M invested in Cymabay Therapeutics in 2023 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 43 increasing their positions, 36 reducing their positions, and 20 closing their positions.
115% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 20
96% more capital invested
Capital invested by funds: $396M → $775M (+$379M)
91% more call options, than puts
Call options by funds: $6.51M | Put options by funds: $3.42M
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
19% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 36
19% more funds holding
Funds holding: 117 → 139 (+22)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$50.1M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$31.2M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$25.6M |
| 4 |
PA
Perceptive Advisors
New York
|
+$25.6M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$21.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$29.7M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$22.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$13.6M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$8.35M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$8.28M |
CBAY Hedge Fund Activity: Q1 2023 in Review
139 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2023, worth a combined $775M — up 96% from $396M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new CBAY positions and 20 closed out — a net gain of 23 holders — while 43 added to existing stakes and 36 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $50.1M. The largest seller was Commodore Capital, cutting an estimated $29.7M.
- 139 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2023, up from 117 in Q4 2022.
- Funds reported $775M of Cymabay Therapeutics stock for Q1 2023, up 96% quarter-over-quarter.
- 43 funds opened new Cymabay Therapeutics positions in Q1 2023 and 20 closed out, a net change of +23 holders.
- The largest Cymabay Therapeutics buyer in Q1 2023 was Janus Henderson Group, an estimated $50.1M added.
- The largest Cymabay Therapeutics seller in Q1 2023 was Commodore Capital, an estimated $29.7M sold.
Based on aggregated 13F filings for Q1 2023.